Breaking News, Collaborations & Alliances

Sabin and ReiThera Enter Clinical Manufacturing Pact

BARDA provides the Sabin Vaccine Institute with additional $20mn for further development of Ebola Sudan and Marburg vaccines

By: Contract Pharma

Contract Pharma Staff

The Sabin Vaccine Institute and its partner ReiThera Srl said that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, has exercised the first two options, valued at $20 million, under the 2019 contract to advance the development of vaccines against Ebola Sudan and Marburg viruses through Phase 2 clinical trials. In September 2019, BARDA awarded Sab...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters